Photo from wikipedia
1. Filewod NC, Lee WL. Inflammation without vascular leakage: science fiction no longer? Am J Respir Crit Care Med 2019;200:1472–1476. 2. Wong HK, Cheung TT, Cheung BM. Adrenomedullin and cardiovascular… Click to show full abstract
1. Filewod NC, Lee WL. Inflammation without vascular leakage: science fiction no longer? Am J Respir Crit Care Med 2019;200:1472–1476. 2. Wong HK, Cheung TT, Cheung BM. Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis 2012;1:1–7. 3. Voors AA, Kremer D, Geven C, Ter Maaten JM, Struck J, Bergmann A, et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail 2019;21:163–171. 4. Brusse-Keizer M, Zuur-Telgen M, van der Palen J, VanderValk P, Kerstjens H, Boersma W, et al. Adrenomedullin optimises mortality prediction in COPD patients. Respir Med 2015;109:734–742. 5. Singh JSS, Burrell LM, Cherif M, Squire IB, Clark AL, Lang CC. Sacubitril/valsartan: beyond natriuretic peptides. Heart 2017;103: 1569–1577. 6. Geven C, Blet A, Kox M, Hartmann O, Scigalla P, Zimmermann J, et al. A double-blind, placebo-controlled, randomised, multicentre, proof-ofconcept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). BMJ Open 2019;9:e024475.
Journal Title: American Journal of Respiratory and Critical Care Medicine
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!